The Dermatology Digest
APRIL 15, 2025
Acclaro Medical is launching AuraLux cold fiber laser, a next generation version of its 2910 nm laser technology. AuraLux was unveiled atThe Medical Spa Show in Las Vegas, NV. AuraLuxs CoolPulsetechnology automatically blends cold ablation and adjustable coagulation to precisely deliver the energy in the same channel for optimal results that minimize pain and downtime on all skin types.
Salon Today
APRIL 15, 2025
Best practices in salon retail as it relates to eCommerce and luxury omnichannel shopping.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Beauty Launchpad
APRIL 15, 2025
Hairstylist Sydney Ann Lopez shares how she's helping fellow hair pros boldly bring their dream brand to life through her custom salon apparel and neon singage.
The Skin Institute
APRIL 15, 2025
Many people are influenced by current health and beauty trends and a recent one is facial rollers. Companies and individuals on social media rave about how these rollers promote better circulation in your face, reduce puffiness, increase glow, and make your skin look more youthful. But are these founded claims?
Beauty Launchpad
APRIL 15, 2025
After an explosive launch in the US market, multiple award winning LOreal Professionnels AirLight Pro is hitting the road as Nikki Glasers must-have beauty tool for her highly anticipated Alive & Unwell comedy tour.
Dermatology Times
APRIL 15, 2025
Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
Dermatology Times
APRIL 15, 2025
The funds will target programs for chronic pruritus, atopic dermatitis, and other inflammatory skin conditions.
Alison Bladh
APRIL 15, 2025
Toxic-Free Living: How to Protect Your Hormones from Hidden Chemicals When we think about hormone health, we often focus on food, stress, sleep and exercise. But theres another important piece of the puzzle that many women overlook the hidden chemicals in our everyday environment that can wreak havoc on our hormones, energy, weight, and overall wellbeing.
Dermatology Times
APRIL 15, 2025
Facial hyperpigmentation may signal systemic disease. Dermatologists must assess beyond melasma to ensure timely, accurate diagnosis and care.
Eminence Organics
APRIL 15, 2025
Our Sustainable Beauty Mission: Land To Sea At Eminence Organic Skin Care , caring for your skin goes hand in hand with caring for the Earth. Our environmental initiatives reflect our belief that skin care and sustainability are deeply connected. With your support, we've planted over 29 million trees Forests for the Future initiative with Trees for the Future.
Dermatology Times
APRIL 15, 2025
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Lipgloss and Aftershave
APRIL 15, 2025
When it comes to skincare that delivers real resultswithout compromise Victoria Tabak , CEO of Nature Pure Holistic Skincare , is changing the game. With over 20 years in the industry, a Masters Degree in Business, and a deep knowledge of ingredient chemistry, shes crafted a line of skincare that bridges nature and clinical performance. Her secret weapon?
Dermatology Times
APRIL 15, 2025
Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimabs efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.
US Dermatologt Partners
APRIL 15, 2025
DALLAS U.S. Dermatology Partners is pleased to announce that 11 of its physicians have been recognized as 2025 Rising Stars by Castle Connolly Top Doctors. 11 Board-Certified Dermatologists at U.S. Dermatology Partners Have Been Named 2025 Rising Stars by Castle Connollys Peer-Nominated Top Doctor Awards Castle Connolly Rising Stars are early career physicians among the top 7% of doctors nationwide recognized for outstanding accomplishments and dedication to the field of medicine.
Dermatology Times
APRIL 15, 2025
Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.
The Dermatology Digest
APRIL 15, 2025
Patients experienced a50% reduction in pruritus severity, withmean scores dropping from 1.6 on Day 1 to 0.8 by Day 21, according to positive interim data from the open-label part of Hoth Therapeutics, Inc.s Phase 2a clinical trial evaluatingHT-001for the treatment ofpruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.
Dermatology Times
APRIL 15, 2025
Improvements in hydration, erythema, itching, and burning were observed after 12 weeks of treatment for papulopustular rosacea.
West Lake Dermatology
APRIL 15, 2025
GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, have revolutionized weight loss by helping individuals shed significant amounts of weight quickly and effectively. Originally developed to manage type 2 diabetes, these medications work by regulating appetite , slowing digestion, and promoting a feeling of fullness. While rapid weight loss offers numerous health benefits such as improved cardiovascular health, reduced risk of diabetes, and enhanced mobility it can also result in e
Dermatology Times
APRIL 15, 2025
Corticosteroids, calcineurin inhibitors, and fractional CO2laser were also effective in achieving high levels of repigmentation.
Dermatology Times
APRIL 15, 2025
In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.
Dermatology Times
APRIL 15, 2025
Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.
Expert insights. Personalized for you.
36 
Let's personalize your content